Operating as a subsidiary of Ktb Tumorforschungs Gmbh (tumor Biology Center) one of the largest privately owned hospitals of this type in Europe, ProQinase GmbH, a contract research organization, engages in the preclinical development of protein kinase inhibitors based on an integrated protein kinase technology (iProKiTe) platform for oncology and other therapeutic areas. The company produces recombinant protein kinases for biochemical kinase activity assays. It also provides various types of compound testing in biochemical assays with protein kinases and lipid kinases; and cellular assay services to characterize compounds on the cellular level. In addition, the company offers a panel of subcuteanous xenografts and orthotopic in vivo tumor models for determining the anti-angiogenic effect of compounds or antibodies against functional human blood vessels in mice. It serves the pharmaceutical industry worldwide.
